$VRDN

Tousignant Jennifer (Chief Legal Officer) sold 14,212 shares of Viridian Therapeutics, Inc.\DE (VRDN) at $24.50 ($0.35M total) across 2 trades on 2026-08-19.

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Lumvoa ™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

Viridian Therapeutics (NASDAQ:VRDN) is discussed after Goldman Sachs raised its price target to $39 from $35 and kept a Buy rating, citing FDA approval-related views on Lumvoa for thyroid eye disease versus Tepezza, including efficacy on proptosis, safety, and easier dosing. Truist also raised its target to $38 from $35, projecting revenue by 2027.

Wells Fargo’s Mason Mendez said investors should stay invested despite volatility, citing a constructive equity view and a 2026 year-end S&P 500 target of 7,800 to 8,000, while noting high Q2 earnings expectations and leverage risks. The article highlights two Wells Fargo stock picks: Advanced Energy Industries (AEIS) and Viridian Therapeutics (VRDN), both with Strong Buy consensus ratings and double-digit upside potential.

Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).

Eurozone June economic confidence rose to 95.0 (+1.3), beating expectations of 94.3, and May M3 money supply increased 3.2% y/y vs 2.7% expected. Markets priced a ~7% chance of a 25 bp ECB hike on July 23. US stocks gained: KLAC +11%, PANW +9%, IRDM +25% on Rocket Lab’s ~$8B deal; several others rose or fell on upgrades, partnerships, and guidance.

Viridian Therapeutics said the U.S. FDA approved Lumvoa (veligrotug-vvze) for thyroid eye disease, its first commercial product. The company said the approval is based on Phase 3 THRIVE and THRIVE-2 trials, which met primary and secondary endpoints with improvements at week 15 in active and chronic TED. Lumvoa is a 12-week course. Viridian added that VRDN stock rose to $17.90 Friday and $19.81 after hours.

Seven Grand Managers LLC bought 100,000 shares of Viridian Therapeutics (NASDAQ:VRDN) in Q4, worth about $3.11M, raising its stake to ~0.10%, according to an SEC filing. Other investors increased positions, including Geode ($62.0M) and Fisher ($55.4M). Viridian reported Q earnings of -$0.90 EPS on $0.14M revenue (May 5).

Viridian Therapeutics (NASDAQ: VRDN) has priced upsized concurrent public offerings totaling $350 million. The financing includes $225 million in 1.75% convertible senior notes due 2032 and an equity offering of over 7.3 million shares at $17.00 per share. Net proceeds will be used to repay debt, fund market expansion studies for its thyroid eye disease franchise, advance early-stage research, and support general working capital.